Skip to main contentSkip to navigationSkip to search

Curasight attends the J.P. Morgan Healthcare Conference and presents at HC Andersen Capital

December 30, 2021


Curasight A/S (“Curasight” or the “Company”) CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær has been invited to J.P. Morgan 40[th] Annual Healthcare Conference which will take place 10-13 January 2022. Furthermore, Curasight will present a Deep Dive event in Brain cancer at HC Andersen Capital, 19 January 2022.

The presentation at HC Andersen Capital will be webcasted live 11:00 - 11:30 (CET), Wednesday 19 January 2022.

For more information please click here

The presentation will be in English.

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60


Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel theranostic platform with Positron Emissions Tomography (PET) imaging  Radionuclide Therapy targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis, risk stratification and therapy in multiple cancer types.